Amyloid PET imaging in patients with mild cognitive impairment: A 2-year follow-up study

Neurology

Volumn 76, Issue 12, 2011, Pages 1085-1090

  Koivunen, J ^a   Scheinin, N ^a   Virta, J R ^a   Aalto, S ^a   Vahlberg, T ^a   Nagren K ^a   Helin, S ^a   Parkkola, R ^b   Viitanen, M ^a   Rinne, J O ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; PITTSBURGH COMPOUND B;

ADULT; AGED; ALZHEIMER DISEASE; AMNESIA; ANTERIOR CINGULATE; ARTICLE; BRAIN ATROPHY; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; FRONTAL CORTEX; HIGH RISK PATIENT; HIPPOCAMPUS; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRIORITY JOURNAL; PUTAMEN; TEMPORAL CORTEX;

EID: 79953177902     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318212015e     Document Type: Article

References (18)

1. Jack CR Jr, Petersen RC, Xu YC, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999;52:1397-1403. (Pubitemid 29190530)
2. Kemppainen NM, Aalto S, Wilson IA, et al. PET amyloid ligand [C-11]PIB uptake is increased in mild cognitive impairment. Neurology 2007;68:1603-1606. (Pubitemid 46717985)
3. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposits in patients with mild cognitive impairment. Neurobiol Aging 2008;29:1456-1465.
4. Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007;130: 2837-2844. (Pubitemid 350033975)
5. Mintun MA, Larossa GN, Sheline YI, et al. [11C] PiB in a nondemented population: potential antecedent marker of Alzheimer's disease. Neurology 2006;67:446-452. (Pubitemid 44214969)
6. Koivunen J, Pirttilä T, Kemppainen N, et al. PET amyloid ligand [C-11]PIB uptake and cerebrospinal fluid betaamyloid in mild cognitive impairment. Dement Geriatr Cogn Disord 2008;26:378-383.
7. Fagan AM, Csernarsky CA, Morris JC, et al. The search for antecedent biomarkers of Alzheimer's disease. J Alzheimer Dis 2005;8:347-358.
8. Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 2009;73:754-760.
9. Drzezga A, Lautenschlanger N, Siebner H, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Molec Imaging 2003;30: 1104-1113. (Pubitemid 36988222)
10. Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006;129:2856-2866. (Pubitemid 44684508)
11. Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PIB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008;131:665-680. (Pubitemid 351294719)
12. Scheinin NM, Aalto S, Koikkalainen J, et al. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer's disease and controls. Neurology 2009;73:1186-1192.
13. Jack CR Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009;132:1355-1365.
14. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183-194. (Pubitemid 39222988)
15. Kemppainen NM, Aalto S, Wilson IA, et al. Voxel-based analysis of PET amyloid ligand [C-11]PIB uptake in Alzheimer disease. Neurology 2006;67:1575-1580. (Pubitemid 44747926)
16. Scheltens P, Leys D, Barkhof F, et al. Atrophy of medial temporal lobes on MRI in probable Alzheimer's disease and normal aging: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992;55: 967-972.
17. Mathis CA, Lopresti BJ, Klunk WE, et al. Impact of amyloid imaging on drug development in Alzheimer's disease. Nucl Med Biol 2007;34:809-822. (Pubitemid 47503823)
18. Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 2009; 106:6820-6825.